{"doc_id": "si-2021-0155-reg-1", "parent_doc_id": "si-2021-0155", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 155 of 2021", "title": "Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the", "year": 2021, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 6) Regulations 2021. \n\n(2) The collective citation “the Medicinal Products (Prescription and \n\nControl of Supply) Regulations 2003 to 2021” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 6) regulation 2021 (2) collective citation medicinal product (prescription control supply) regulation 2003 2021 includes regulation", "start_char": 644, "end_char": 934, "source_path": "downloads\\2021\\2021_0155.pdf", "extraction_method": "pdfminer", "checksum": "sha256:38c4c66ad987804ddf14c43e5f616f6c32ab2743e8d298246bdc596c3cbb0117", "cross_refs": []}
{"doc_id": "si-2021-0155-reg-2", "parent_doc_id": "si-2021-0155", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 155 of 2021", "title": "Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the", "year": 2021, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and \nControl of Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2021” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 3) Regulations 2021 (S.I. No. 43 of 2021).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2021 mean medicinal product (prescription control supply) (amendment) (no 3) regulation 2021 (s.i no 43 2021)", "start_char": 934, "end_char": 1248, "source_path": "downloads\\2021\\2021_0155.pdf", "extraction_method": "pdfminer", "checksum": "sha256:38c4c66ad987804ddf14c43e5f616f6c32ab2743e8d298246bdc596c3cbb0117", "cross_refs": []}
{"doc_id": "si-2021-0155-reg-3", "parent_doc_id": "si-2021-0155", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 155 of 2021", "title": "Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the", "year": 2021, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations of", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations of \n2021) to the Principal Regulations is amended by inserting the following entry: \n\nRoute of \nadministration \n\nColumn 3 \nIntramuscular \n(IM) injection \nonly. \n\n“ \nMedicinal \nProduct \n\nColumn 1 \nCOVID-19 \nVaccine \nJanssen \nsuspension for \ninjection \n(Ad26.COV2S \n[recombinant]). \n\nForm and \npresentation \nof product \nadministered \n\nColumn 2 \nSuspension \nfor injection. \nColourless \nto slightly \nyellow, clear \nto very \nopalescent \nsuspension \n(pH 6-6.4). \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \nColumn 4 \nCOVID-19 \nVaccine \nJanssen is \nindicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV2 in \nindividuals \n18 years of \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministration \n\nColumn 5 \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand relevant \nnational \nguidelines. \n\nColumn 6 \nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 6th April, 2021. \n\n \n \n \n \n \n \n \n \n \n \n\fage and \nolder. \n\n[155] 3 \n\nadminister the \nproduct. \n\n”.", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2021) principal regulation amended inserting following entry route administration column 3 intramuscular (im) injection only medicinal product column 1 covid-19 vaccine janssen suspension injection (ad26.cov2s recombinant ) form presentation product administered column 2 suspension injection colourless slightly yellow clear opalescent suspension (ph 6-6.4) indication medicinal product may administered column 4 covid-19 vaccine janssen indicated active immunisation prevent covid-19 caused sars-cov2 individual 18 year dosage condition administration place administration column 5 accordance summary product characteristic product administered relevant national guideline column 6 suitable appropriate place regard public convenience need protect health safety public safely notice making statutory instrument published iris oifigiuil 6th april 2021 age older 155 3 administer product", "start_char": 1248, "end_char": 2564, "source_path": "downloads\\2021\\2021_0155.pdf", "extraction_method": "pdfminer", "checksum": "sha256:38c4c66ad987804ddf14c43e5f616f6c32ab2743e8d298246bdc596c3cbb0117", "cross_refs": []}
{"doc_id": "si-2021-0155-reg-4", "parent_doc_id": "si-2021-0155", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 155 of 2021", "title": "Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the", "year": 2021, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations of", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations of \n2021) to the Principal Regulations is amended by inserting the following entry: \n\n“ \n\nMedicinal Product \n\nForm and \npresentation of \nproduct \nadministered \n\nRoute of \nadministration \n\nIndication for \nwhich the \nmedicinal product \nmay be \nadministered \n\nDosage and \nconditions of \nadministration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nIntramuscular \n(IM) injection \nonly. \n\nCOVID-19 Vaccine \nJanssen suspension \nfor injection \n(Ad26.COV2-S \n[recombinant]). \n\nSuspension for \ninjection. \nColourless to \nslightly yellow, \nclear to very \nopalescent \nsuspension (pH \n6-6.4). \n\nCOVID-19 \nVaccine Janssen is \nindicated for \nactive \nimmunisation to \nprevent COVID19 caused by \nSARS-CoV-2 in \nindividuals 18 \nyears of age and \nolder. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics of \nthe product \nadministered and \nrelevant national \nguidelines. \n\n”. \n\nGIVEN under my Official Seal, \n\n31 March, 2021. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f4 [155]", "text_norm": "4 twelfth schedule (as amended regulation 4 regulation 2021) principal regulation amended inserting following entry medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration column 1 column 2 column 3 column 4 column 5 intramuscular (im) injection only covid-19 vaccine janssen suspension injection (ad26.cov2-s recombinant ) suspension injection colourless slightly yellow clear opalescent suspension (ph 6-6.4) covid-19 vaccine janssen indicated active immunisation prevent covid19 caused sars-cov-2 individual 18 year age older accordance summary product characteristic product administered relevant national guideline  given official seal 31 march 2021 stephen donnelly minister health 4 155", "start_char": 2564, "end_char": 3660, "source_path": "downloads\\2021\\2021_0155.pdf", "extraction_method": "pdfminer", "checksum": "sha256:38c4c66ad987804ddf14c43e5f616f6c32ab2743e8d298246bdc596c3cbb0117", "cross_refs": []}
{"doc_id": "si-2021-0155-explanatory-note", "parent_doc_id": "si-2021-0155", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 155 of 2021", "title": "Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the", "year": 2021, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to add an additional Covid-19 vaccination \nto the Eighth and Twelfth Schedules to the Regulations of 2003. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 6) Regulations 2021. \n\n \n \n \n \n \n \n \n\f[155] 5 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \n52 FAICHE STIABHNA, BAILE ÁTHA CLIATH 2, \nD02 DR67. \n\nTeil: 076 110 6834 \nr-post: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \n52 ST. STEPHEN'S GREEN, DUBLIN 2, \nD02 DR67. \n\nTel: 076 110 6834 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-220) 75. 3/21. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation add additional covid-19 vaccination eighth twelfth schedule regulation 2003 regulation may cited medicinal product (prescription control supply) (amendment) (no 6) regulation 2021 155 5 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais 52 faiche stiabhna baile atha cliath 2 d02 dr67 teil 076 110 6834 r-post publication opw.ie ------------ dublin published stationery office purchased government publication 52 st stephen green dublin 2 d02 dr67 tel 076 110 6834 e-mail publication opw.ie ------------ eur 3.00 (dh-220) 75 3 21 propylon", "start_char": 3660, "end_char": 4634, "source_path": "downloads\\2021\\2021_0155.pdf", "extraction_method": "pdfminer", "checksum": "sha256:38c4c66ad987804ddf14c43e5f616f6c32ab2743e8d298246bdc596c3cbb0117", "cross_refs": []}
